Midicial herbal compound for prevention and treatment of diabetes

A composition and hypoglycemic technology, applied in the herbal composition for the prevention or treatment of diabetes, in the field of prevention or treatment of diabetes, which can solve the problems of increasing cardiovascular mortality and the like

Inactive Publication Date: 2006-08-02
HOLOMED PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Major side effects of biguanides are lactic acidosis and increased cardiovascular mortality

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Midicial herbal compound for prevention and treatment of diabetes
  • Midicial herbal compound for prevention and treatment of diabetes
  • Midicial herbal compound for prevention and treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1 - Materials and methods - Extraction of medicinal plants

[0111] Flowering palm trees are grown in India; the inside of the trunk is collected and dried. Mulberry is grown in Korea and northern China; the leaves and roots are collected and dried. Ginseng is grown in Vietnam; the whole plant, including roots, branches, and leaves, is collected and dried. Ophiopogon japonicus, Rosa rugosa var typica (Regel) and Trichosanthes rugosa (Maxim) and Anemarrhena (Bunge) are grown in Korea and northern China; the roots are collected and dried. Commelina (L.) is grown in Korea and China; leaves, stems and flowers are collected and dried. Grind each dry ingredient into powder and mix (Flower Palm (about 20%), Ginseng (about 20%), Mulberry (about 15%), Ophiopogon japonicus (about 10%), Trichosanthes (about 10%), Anemarrhena (about 10%), Rose (about 8%) and Commelina (about 7%) w / w). Boil 40g of combined plant powder and 200ml of water in a slow cooker until the volume...

Embodiment 2

[0112] Example 2 - Goto-Kakizaki (GK) Rats

[0113] GK rats (Goto Y et al., Spontaneous diabetes produced by selective feeding of normal Wistar rats, Proc. Japan. Acad. 51:80-85, 1975; Sugiyama Y et al., Hypoglycemia produced in spontaneously diabetic GK rats The role of hepatic insulin sensitivity, J.Japan.Diab.Soc., 32:593-599, 1989) is one of the best animals to study NIDDM, because most of these animals develop diabetes at about 3 months of age, and diabetes Symptoms share many pathological features with human NIDDM. GK rats display impaired insulin secretion and peripheral insulin resistance. Insulin response, sensitivity to glycogen synthesis, lipogenesis, and DNA synthesis in hepatocytes of GK rats were significantly decreased compared with non-diabetic control rats. In GK rats, the islet architecture was disrupted, and areas of distinct fibrosis were seen in the stroma. As the disease progressed, beta-cell degranulation was observed, whereas lymphocytic infiltration...

Embodiment 3

[0114] Example 3 - Administration of MHCTD to GK Rats

[0115] In order to study the control of blood glucose by MHCTD in diabetic GK rats, 3-month-old rats were treated with the above-prepared MHCTD for 5 months. Animals were gavaged daily (10 am) with 2.5 ml (5 g / kg body weight). Age- and sex-matched GK rats were gavaged with an equal volume of water as controls. Blood glucose levels were measured weekly with a One Touch glucose meter until 1 year old.

[0116] To study the effect of MHCTD on the prevention of diabetes, GK rats were treated with MHCTD from 3 weeks of age before the onset of NIDDM. Rats were gavaged daily with MHCTD (5 g / kg body weight) or water as described above until 13 weeks of age and blood glucose levels were measured weekly until 13 weeks of age.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Description

field of invention [0001] The present invention relates to herbal compositions for preventing or treating diabetes. The invention also relates to a method of preventing or treating diabetes by administering the composition to an individual. Background of the invention [0002] Diabetes is a common serious disease characterized by high blood sugar. The disease can be divided into two broad categories: insulin-dependent diabetes mellitus (IDDM), also known as type I diabetes, and non-insulin-dependent diabetes mellitus (NIDDM), also known as type II diabetes (World Health Organization Study Group, Diabetes, WHO Tech. Rep. Ser. 727:1-113, 1985). IDDM is caused by insulin deficiency due to cell-mediated autoimmune destruction of pancreatic β-cells and usually occurs in infancy (Yoon JW, Insulin-Dependent Diabetes Mellitus, In Roitt IM and Delves PJ (Eds.), Encyclopedia Immunology. of Immunology), 2nd ed., Academic Press Ltd., London, pp. 1390-1398; Bach JF, Insulin-dependent ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/605A61K125/00A61K36/48A61K36/738A61K133/00A61K36/8968A61K36/53A61K36/185A61K36/428A61K131/00A61K36/8964A61P3/10A61K31/4415A61K31/455A61K31/714A61K33/24A61K33/30A61K33/32A61K36/00A61K36/254A61K36/28A61K36/41A61K36/45A61K36/79A61K36/88A61K36/8962A61P43/00
CPCA61K33/32A61K36/48A61K36/88A61K36/79A61K36/185A61K36/41A61K36/254A61K36/605A61K31/455A61K36/8964A61K36/8962A61K36/738A61K36/8968A61K33/30A61K36/53A61K36/28A61K36/45A61K36/428Y10S514/866A61K33/24A61K31/4415A61P43/00A61P3/10A61K2300/00
Inventor 尹址洹全喜淑
Owner HOLOMED PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap